BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 25456366)

  • 1. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
    Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
    Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.
    Mehra R; Udager AM; Ahearn TU; Cao X; Feng FY; Loda M; Petimar JS; Kantoff P; Mucci LA; Chinnaiyan AM
    Eur Urol; 2016 Oct; 70(4):549-552. PubMed ID: 26724257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.
    Lalonde E; Ishkanian AS; Sykes J; Fraser M; Ross-Adams H; Erho N; Dunning MJ; Halim S; Lamb AD; Moon NC; Zafarana G; Warren AY; Meng X; Thoms J; Grzadkowski MR; Berlin A; Have CL; Ramnarine VR; Yao CQ; Malloff CA; Lam LL; Xie H; Harding NJ; Mak DYF; Chu KC; Chong LC; Sendorek DH; P'ng C; Collins CC; Squire JA; Jurisica I; Cooper C; Eeles R; Pintilie M; Dal Pra A; Davicioni E; Lam WL; Milosevic M; Neal DE; van der Kwast T; Boutros PC; Bristow RG
    Lancet Oncol; 2014 Dec; 15(13):1521-1532. PubMed ID: 25456371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer.
    Mehra R; Shi Y; Udager AM; Prensner JR; Sahu A; Iyer MK; Siddiqui J; Cao X; Wei J; Jiang H; Feng FY; Chinnaiyan AM
    Neoplasia; 2014 Dec; 16(12):1121-7. PubMed ID: 25499224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
    Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity.
    Kidd SG; Carm KT; Bogaard M; Olsen LG; Bakken AC; Løvf M; Lothe RA; Axcrona K; Axcrona U; Skotheim RI
    Neoplasia; 2021 Jun; 23(6):634-641. PubMed ID: 34107378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
    Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
    Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
    Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
    Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of age on biochemical recurrence after radical prostatectomy.
    Ozden C; Aktas BK; Bulut S; Erbay G; Tagci S; Gokkaya CS; Baykam MM; Memis A
    Kaohsiung J Med Sci; 2017 Feb; 33(2):91-95. PubMed ID: 28137417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.
    Long Q; Johnson BA; Osunkoya AO; Lai YH; Zhou W; Abramovitz M; Xia M; Bouzyk MB; Nam RK; Sugar L; Stanimirovic A; Williams DJ; Leyland-Jones BR; Seth AK; Petros JA; Moreno CS
    Am J Pathol; 2011 Jul; 179(1):46-54. PubMed ID: 21703393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.
    Erho N; Crisan A; Vergara IA; Mitra AP; Ghadessi M; Buerki C; Bergstralh EJ; Kollmeyer T; Fink S; Haddad Z; Zimmermann B; Sierocinski T; Ballman KV; Triche TJ; Black PC; Karnes RJ; Klee G; Davicioni E; Jenkins RB
    PLoS One; 2013; 8(6):e66855. PubMed ID: 23826159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SIGNIFICANCE OF INTRADUCTAL CARCINOMA OF THE PROSTATE IN POST-OPERATIVE BIOCHEMICAL RECURRENCE].
    Sakamoto N; Ueda S; Mizoguchi H; Kawahara I; Kobayashi T; Hamaguchi M; Yoshikawa M
    Nihon Hinyokika Gakkai Zasshi; 2017; 108(1):5-11. PubMed ID: 29367511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
    Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
    Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The meaning of PSA progression after radical prostatectomy. Preliminary results].
    Luján Galán M; Pascual Mateo C; Rodríguez García N; Chiva Robles V; Escalera Almendros C; Angulo Cuesta J; Berenguer Sánchez A
    Actas Urol Esp; 2006 Apr; 30(4):353-8. PubMed ID: 16838606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.